Clinical Trials · NCT04130152
Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy
- Phase
- EARLY_Phase 1
- Recruitment status
- Completed
- Sponsor
- SOLTI Breast Cancer Research Group
- Enrollment
- 22
- Start date
- Nov 2019
- Locations
- 8 sites, Spain
- Primary endpoint
- Complete Cell Cycle Arrest (CCCA)